Pfizer's Xalkori picks up FDA nod for rare ALK-positive tumors

First endorsed 11 years ago for anaplastic lymphoma kinase (ALK)-positive lung cancer, Pfizer’s Xalkori is being surpassed in that indication by the company’s own Lorbrena and Takeda’s Alunbrig.